Advertisement
UK markets closed
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     
  • AIM

    771.53
    +3.42 (+0.45%)
     
  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     
  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     
  • Bitcoin GBP

    50,120.14
    +2,865.93 (+6.06%)
     
  • CMC Crypto 200

    1,366.22
    +89.24 (+6.98%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +450.02 (+1.18%)
     
  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     

Ophthotech (OPHT) Jumps: Stock Rises 11.9%

Ophthotech Corporation OPHT was a big mover last session, as the company saw its shares rise nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $69.68–$76.25 in the past one-month time frame, witnessed a sharp increase yesterday.

The Zacks Consensus Estimate for the current quarter has moved lower in the past 60 days, suggesting that there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.   

Ophthotech currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Ophthotech Corporation Price and Consensus

Ophthotech Corporation Price and Consensus | Ophthotech Corporation Quote

ADVERTISEMENT

A better ranked stock in the  Medical - Biomedical and Genetics industry is Myriad Genetics, Inc. MYGN which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is OPHT going up? Or down? Predict to see what others think:Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report
 
Ophthotech Corporation (OPHT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research